Concepedia

S. Iqbal

SI

Statistics

Publications

3

Citations

62

H-Index

3

Active since

2010

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

S. Iqbal is an author at The University of Texas MD Anderson Cancer Center specializing in open-label trials, recist criteria, and gastric cancer pharmacotherapy.

ORCID

Publications per year

2010–2025

3

Publications

3

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg et al. · Journal of Clinical Oncology · 2024 · 28 citations · Full text

, , +17

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study

Elena Elimova, Jaffer A. Ajani, Howard A. Burris et al. · The Lancet Oncology · 2025 · 24 citations

, , +8

Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).

M. B. Sawyer, S. Iqbal, H. Lenz et al. · Journal of Clinical Oncology · 2010 · 10 citations

, , +16

1–3 of 3